Pylarify (fluorine-18 piflufolastat) injection

Active Blanket Purchase Agreement Awarded Last action

Contract number
HT941023A0002
Awardee
Awarding agency
Task orders
6 $245,393 obligated

Award facts

Opportunity
Combined order value
$245,393 Current and potential, with all options
Last date to order 74% complete
IDV ceiling 25% used
$1,000,000.00
Maximum order
$50,000.00
Award type
Single award
Who can order
Only the awarding agency
Contracting staff
Set-aside
No set-aside
Pricing
Firm Fixed Price

Award details come from SAM.gov/FPDS.

About this IDV

The Defense Health Agency (DHA) awarded a Blanket Purchase Agreement (BPA) to Progenics Pharmaceuticals Inc., a subsidiary of Lantheus Holdings, Inc., for the delivery of PYLARIFY (piflufolastat F-18) injection, a radioactive diagnostic agent used in positron emission tomography (PET) scans to detect and image prostate cancer. The BPA has a ceiling value of $1,000,000 and a period of performance through January 31, 2028. The contract is not set aside for small businesses. Under this BPA, the DHA has issued several task orders to Progenics Pharmaceuticals for the supply of PYLARIFY, with individual order values ranging from approximately $21,000 to $47,000. These firm fixed-price BPA calls support the DHA's efforts to provide critical radiopharmaceutical products to military treatment facilities and other federal healthcare providers. Lantheus Holdings and its subsidiaries are major suppliers of radiopharmaceuticals and medical imaging agents to federal agencies, including the Department of Veterans Affairs and DHA, through various Indefinite Delivery Vehicles.

The original solicitation was a notice of intent to award a sole source BPA to Progenics Pharmaceuticals, as the sole manufacturer and authorized supplier of PYLARIFY. The notice was posted by the DHA's Western Markets Contracting Division, with the objective of establishing a BPA for PYLARIFY supplies to support the Naval Medical Center San Diego. The potential period of performance for the BPA was January 1, 2023 through December 31, 2028, and the NAICS code was 325412 for pharmaceutical preparation manufacturing.

Task orders

Task order Ordering agency Obligated Awarded
Pylarify (piflufolastat f-18) injection HT941024F0013 Defense Health Agency $21,652
Pylarify (piflufolastat f-18) injection HT941023F0177 Defense Health Agency $46,913
Pylarify (piflufolastat f-18) injection HT941023F0139 Defense Health Agency $36,087
Pilarify (piflufolastat f-18) injection HT941023F0106 Defense Health Agency $46,913
Pilarify (piflufolastat f-18) injection x 13 HT941023F0069 Defense Health Agency $46,913
Pilarify (piflufolastat f 18) injection x 13 HT941023F0047 Defense Health Agency $46,913

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00001 · Pylarify (piflufolastat f 18) injection $0
Original award $0

Quick answers

Who was awarded contract HT941023A0002?

HT941023A0002 was awarded to Progenics Pharmaceuticals Inc. by Defense Health Agency (Department of Defense) on February 1, 2023.

How much is contract HT941023A0002 worth?

Orders under HT941023A0002 have obligated $245,393. HT941023A0002's own ceiling is $1,000,000. A single order can be worth up to $50,000.

How many orders have been placed under contract HT941023A0002?

6 orders have been placed under HT941023A0002, the latest on November 21, 2023.

Who can order from contract HT941023A0002?

HT941023A0002 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV